Clinical Developments

TREKKA continually assesses and identifies market opportunities to identify the most compatible APIs to combine with our CAPRO technology. As opportunities present themselves, TREKKA often seeks out options to advance its own development portfolio of proprietary and/or partnered pharmaceutical products.

Consequently, our CAPRO Polymer Drug Delivery Platform has allowed us to explore a new innovative formulation to address melanoma cancer in the form of a vaccine. This new API is in pre-market development in collaboration with the Mayo Clinic after attaining a Phase I STTR grant from the National Institutes of Health (NIH).

Additionally, we have forged a development partnership with Centrea Biopharmaceuticals to develop a long duration pain management therapeutic for surgical, dental and post operative conditions.